AbbVie Expands Manufacturing Presence with US$320 Million Investment in Singapore

   AbbVie Expands Manufacturing Presence with US$320 Million Investment in
                                  Singapore

  PR Newswire

  NORTH CHICAGO, Illinois, Feb. 6, 2014

NORTH CHICAGO, Illinois, Feb. 6, 2014 /PRNewswire/ --AbbVie Inc. (NYSE:
ABBV) announces a US$320 million [approximately S$400 million] investment to
establish operations in Singapore for small molecule and biologics active drug
substance manufacturing. The completed facility will provide manufacturing
capacity for emerging compounds within AbbVie's oncology and immunology
pipeline to serve markets globally.

The investment will establish the first manufacturing presence in Asia by
AbbVie. Other AbbVie operations in Asia include research and development (R&D)
functions in Tokyo, Japan and Shanghai, China, as well as commercial
operations throughout the region. AbbVie's existing presence in Singapore
includes 120 personnel, supporting commercial operations, global R&D and
general operations.

"As Asia's fastest-growing bio-cluster, Singapore is an ideal location to
expand our manufacturing network while maintaining rigorous standards of
quality and delivery for the patients we serve around the world," said Azita
Saleki-Gerhardt, Ph.D., Senior Vice President, Operations, AbbVie. "Our
presence in Singapore will help assure geographic balance and continuity of
product supply as well as increased capacity to deliver on our growing
biologics and small molecule product pipeline."

"We are very pleased that Singapore will host AbbVie's first manufacturing
facility in Asia. This investment is a testament of Singapore's strong
biologics manufacturing capabilities. To support the continued growth of this
sector, Singapore will be investing heavily in human capital development, and
new programs will be put in place to train biologics manufacturing talent
ahead of demand," said Kevin Lai, Director, Biomedical Sciences of the
Singapore Economic Development Board.

The investment is expected to result in additional headcount of more than 250
new employees. AbbVie anticipates the new facility will be fully operational
by 2019.

AbbVie is focused on delivering its small molecule and biologics pipeline to
address significant unmet medical needs and advance the wellbeing of patients
across the following therapeutic areas: immunology, liver disease, oncology,
neuroscience and kidney disease. The company's unique offerings stem from its
125-year pharmaceutical development heritage combined with the innovative
focus of a biotech.

AbbVie's current manufacturing network includes 12 sites across the United
States, Europe and Puerto Rico, as well as strategic partnerships with
third-party manufacturers.

About AbbVie AbbVie is a global, research-based biopharmaceutical company
formed in 2013 following separation from Abbott. The company's mission is to
use its expertise, dedicated people and unique approach to innovation to
develop and market advanced therapies that address some of the world's most
complex and serious diseases. AbbVie employs approximately 25,000 people
worldwide and markets medicines in more than 170 countries. For further
information on the company and its people, portfolio and commitments, please
visit www.abbvie.com . Follow @abbvie on Twitter or view careers on our
Facebook or LinkedIn page.

Website: http://www.abbvie.com
Contact: Media, Adelle Infante, +1 (847) 938-8745, or Investors: Liz Shea, +1
(847) 935-2211
 
Press spacebar to pause and continue. Press esc to stop.